ProKidney Corp. (PROK)

2.3900 +0.1500 (+6.70%) At close: 04:00PM EDT

ProKidney Corp.

2000 Frontis Plaza Blvd.
Suite 250
Winston-Salem, NC 27103
United States
336 999 7028
https://www.prokidney.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 163

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Bruce Culleton M.D.	CEO & Director	657.93k	N/A	1968
Dr. Timothy A. Bertram D.V.M., Ph.D.	Founder	1.46M	N/A	1955
Mr. Todd C. Girolamo Esq., J.D., M.B.A.	Chief Legal Officer & Secretary	541.59k	N/A	1965
Ms. Mary Weger	Chief People Officer	N/A	N/A	1959
Dr. Joseph M. Stavas M.D., M.P.H.	Senior VP of Interventional Procedures & Patient Safety	N/A	N/A	N/A
Dr. Darin J. Weber Ph.D.	Chief Reg. Off, SVP and Head of Global Reg. Affairs, Quality Mgmt, Biometrics & Market Access	N/A	N/A	1968
Mr. Nikhil L. Pereira-Kamath	Chief Business Officer	N/A	N/A	N/A
Mr. Richard Williams	Senior Vice President of Information Technology	N/A	N/A	N/A
Dr. Aparna Sahoo M.D.	VP & Head of Global Clinical Development	N/A	N/A	N/A
Emily Butler Ph.D.	Senior VP of Biometric	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Corporate governance

ProKidney Corp.’s ISS governance QualityScore as of 1 May 2024 is 8. The pillar scores are Audit: 10; Board: 7; Shareholder rights: 4; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.